Latest research findings on urologic disease to be presented at 2000 American Urological Association annual meeting
April 25, 2000Scheduled for April 29 -- May 4 in Atlanta More than 1,500 original research studies on the prevention, diagnosis, treatment, and management of urologic diseases plus state-of-the-art plenary session presentations highlight the program for the 2000 American Urological Association Annual Meeting, scheduled for April 29 -- May 4 at Atlanta's Georgia World Congress Center.
More than 8,000 urologists will attend the meeting‹the largest and most comprehensive annual forum devoted exclusively to urology. Total attendance is expected to exceed 14,000 registrants, including non-urologist physicians, biomedical researchers and health care professionals. In addition to numerous podium and poster sessions at which new research findings will be presented, meeting registrants will be able to attend state-of-the-art lectures, panel discussions, point/counterpoint debates on controversial issues in urology, continuing education courses, and a exposition of over 300 exhibits demonstrating the latest products and technology of interest to urologists.
During the meeting, new research findings and state-of-the-art information will be presented on all urologic diseases, including prostate cancer, male and female sexual dysfunction, incontinence, benign prostatic hyperplasia or enlarged prostate, kidney stone disease, bladder cancer, testicular cancer, kidney cancer and infertility.
Highlights of the plenary program include:
- Panel discussion on "Advances in Bladder Augmentation and Replacement," scheduled for Sunday, April 30 at 10:50 a.m. Panelists include Dr. Terry W. Hensle of the Babies Hospital in New York City, Dr. Anthony Atala of the Children's Hospital in Boston, Dr. Bradley P. Kropp of the University of Oklahoma, and Dr. Richard C. Rink of the Riley Hospital for Children at the University of Indiana Medical Center.
- State-of-the-art lecture by Dr. Mark S. Litwin of the University of California, Los Angeles on "Prostatitis: Changing Concepts," scheduled for Sunday, April 30 at 11:25 a.m.
- Point/counterpoint discussion on "Stress Urinary Incontinence: Approaches to Evaluation and Management," scheduled for Monday, May 1 at 8 a.m. The discussion will be moderated by Dr. Alan J. Wein from the Hospital of the University of Pennsylvania in Philadelphia, and the subject will be discussed by Dr. Paul Abrams from Bristol, England and Dr. Robert J. Krane from Boston University Medical Center.
- State-of-the-art lecture by Dr. Michael J. Droller of the Mount Sinai Medical Center in New York City on "Molecular Markers in Diagnosis of Carcinoma of the Bladder," scheduled for Monday, May 1 at 8:20 a.m.
- State-of-the-art lecture by Dr. Lawrence H. Einhorn of the Indiana Cancer Pavilion in Indianapolis on "The Management of Testicular Cancer," scheduled for Monday, May 1 at 9:30 a.m.
- State-of-the-art lecture by Dr. William R. Fair of Memorial Sloan-Kettering Cancer Center in New York City on "Alternative/Complementary Medicine: Current Approaches," scheduled for Monday, May 1 at 11:45 a.m.
- State-of-the-art lecture by Dr. Gary E. Leach of the Tower Urology Institute for Continence in Los Angeles on "Sling Procedures for Stress Urinary Incontinence," scheduled for Tuesday, May 2 at 8 a.m.
- State-of-the-art lecture by Dr. Howard I. Scher of Memorial Sloan-Kettering Cancer Center in New York City on "New Approaches to Hormonal Management in Carcinoma of the Prostate," scheduled for Tuesday, May 2 at 8:20 a.m.
- Panel discussion on "Renal Cell Carcinoma: Clinical Problems," scheduled for Tuesday, May 2 at 8:40 a.m. Panel members include Dr. Jerome P. Richie from Brigham & Women's Hospital in Boston, Dr. Rolf Ackerman from the University of Dusseldorf, Dr. Steven C. Campbell from Northwestern University, Jean B. deKernion from the University of California, Los Angeles, and Dr. Robert C. Flanigan from Loyola University Medical Center.
- Point/counterpoint discussion on "Management of T3 Cancer of the Prostate," scheduled for Wednesday, May 3 at 8:40 a.m. The moderator of this discussion will be Dr. Andrew C. von Eschenbach of the University of Texas M.D. Anderson Cancer Center. The subject will be discussed by Dr. William J. Catalona from the Washington University Medical Center in St. Louis and Dr. William U. Shipley from the Massachusetts General Hospital Cancer Center in Boston.
- The John K. Lattimer Lecture will be presented on Wednesday, May 3 at 9:10 a.m. by Dr. Thomas A. Stamey of Stanford Medical Center, who will discuss "Prostate Cancer: Predicting Outcomes."
- The Ramon Guiteras Lecture will be presented on Wednesday, May 3 at 11:25 a.m. by Dr. Ralph V. Clayman of Applied Medical Resources, who will discuss "Surgical Implosion: The Waning of the Wound." Being invited to present the Guiteras Lecture represents one of the most prestigious honors that takes place at each AUA Annual Meeting.
- Latest data on the high costs of prostate cancer.
- Data that addresses the relationship between prostate specific antigen (PSA) screening and prostate cancer mortality.
- The quality of life after radical prostatectomy vs. brachtherapy for localized prostate cancer.
- Outcomes information on sexual function after Cavermap™ assisted nerve-sparing radical prostatectomy.
- Data that shows topical alprostadil produces significant clitoral hemodynamic changes.
- Outcomes data on the effects of sildenafil on sexual function in hysterectomy patients.
- The efficacy and safety of apomorphine for erectile dysfunction in patients with coronary artery disease.
- Latest information on penile reconstruction using engineered corporal tissue.
-end-
For more information about the AUA Annual Meeting, please contact Bill Glitz by phone at 703-532-3797 or by email at wglitz@aol.com; or Lisa Goetz by phone at 410-223-6402 or by email at lgoetz@auanet.org. The telephone number for the press room in Atlanta is 404-222-5203. It will be activated on April 28 and discontinued at 12 noon on May 4.American Urological Association
Related Prostate Cancer Articles from Brightsurf:
Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).
ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.
Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.
The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.
Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.
First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
Read More: Prostate Cancer News and Prostate Cancer Current Events
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).
ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.
Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.
The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.
Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.
First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.